Infection and atherosclerosis;Infección y aterosclerosis

Revista Espanola de Cardiologia

Volumn 54, Issue 3, 2001, Pages 383-392

  Gurfinkel, Enrique P ^a  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN FAVALORO   (Argentina)

Author keywords

Atherosclerosis; Infection; Inflammation; Inmunology

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; INTERFERON; MACROLIDE; ROXITHROMYCIN;

ANTIBIOTIC THERAPY; ATHEROSCLEROSIS; CANCER; CAUSE OF DEATH; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CYTOTOXICITY; DIARRHEA; HUMAN; IMMUNOLOGY; INFECTION; INFLAMMATION; LIFE EXPECTANCY; LYMPHOCYTE ACTIVATION; NATURAL KILLER CELL; PHAGOCYTOSIS; PNEUMONIA; REVIEW; SANITATION; TUBERCULOSIS;

EID: 14344273518     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-8932(01)76316-6     Document Type: Article

References (49)

1. Braunwald E. Shattuck Lecture- Cardiovascular medicine at the turn of the millennium: Triumphs, concerns, and opportunities. N Engl J Med 1997; 337: 1360-1369.
2. Braunwald E, Fuster V. Unstable angina. Definition, pathogenesis, and classification. En: Fuster V, Toss R, Topol EJ, editores. Atherosclerosis and coronary artery disease. Filadelfia: JB Lippincot, 1996; 1285-1298.
3. Gurfinkel E, Bozovich G, Mejaíl I, Cerdá M, Oxilia A, Mautner B. Time significance of acute thrombotic reactant markers in patients with and without silent myocarclial ischemia and overt unstable angina. Am J Cardiol 1995; 76: 121-124.
4. Cohen M, Derners C, Gurfinkel E, Turpie AGG, Fromell GJ, Goodman S et al. Efficacy and safety of enoxaparin in non Q wave coronary syndromes. The ESSENCE Study. N Engl J Med 1997; 337: 447-452.
5. Van der Wal AC, Becker A, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994; 90: 1662-1668.
6. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126.
7. Galis ZS, Suhkova GK, Lark MW, Libby P. Increased expression of matrix mettalloproteinases and matrix degrading activity in vulnerable regions of human athersclerotic plaques. J Clin Invest 1994; 94: 2493-2503.
8. Ross R, Glomset JA. The pathogenesis of atherosclerosis. N Engl J Med 1976; 295: 369-377.
9. Dirksen MT, Var der Wal AC, Van den Berg FM, Van der Loos CM, Becker AE. Distribution of inflammatory cells in atherosclerotic plaques relates to the direction of flow. Circulation 1998; 98: 2000-2003.
10. Cooke PJ. The role of endothelium in atherosclerosis. En: Schultheiss H, Schwimmbeck P, editores. The role of immune mechanisms in cardiovascular disease. Berlín: Springer, 1997; 194-204.
11. Moreno PR, Fallon JT. Inflammation in acute coronary syndromes. En: Schultheiss H, Schwimmbeck P, editores. The role of immune mechanisms in cardiovascular disease. Berlin: Springer. 1997; 213-29.
12. Liuzzo G, Goronzy JJ, Yang H, Kopecky SL, Holmes DR, Frye RL et al. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation 2000; 102: 2883-2888.
13. van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of dominat plaque morphology. Circulation 1994; 89: 36-44.
14. Tannenbaum SH, Finko R, Cines DB. Antibody and immune complexes induce tissue factor production by human endothelial cells. J Immunol 1986; 137: 1532-1537.
15. Buffon A, Liuzzo G, Donofrio G, Biassuci LM, Maseri A. Intracardiac activatior of neutrophils in unstable angina patients is unrelated to culprit lesion. Circulation 1996; 94 (Supl): 514.
16. Fabricant CG, Fabricant J, Litrenta MM, Minick CR. Virus-induced atherosclerosis. J Exp Med 1978; 148: 335-340.
17. Fabricant CG, Hajjar DP, Minnick CR, Fabricant J. Herpesvirus infection enhances cholesterol and cholesteryl ester accumulation in cultured arterial smooth muscle cells. Am J Path 1981; 105: 176-184.
18. Hajjar DP, Fabricant CG, Minick CR, Fabricant J. Virus-induced atherosclerosis. Herpesvirus infection alters aortic cholesterol metabolism and accumulation. Am J Path 1986; 122: 62-70.
19. Nieto FJ, Adam E, Sorlie P, Farzadeegan H, Melnick JL, Comstock GW et al. Cohort study of cytomegalovirus infection as a risk factor for carotid intimal-medial thickening, a measure of subclinical atherosclerosis. Circulation 1996; 94: 922-927.
20. Gurfinkel EP. Rozlosnik J, Bozovich G, Duronto E, Dos Santos A, Mautner B. IgG antibodies to Chamydia and Mycoplasma infection plus C reactive protein related to poor outcome in unstable angina. Archives del Instituto de Cardiología de México 1997; 67: 462-468.
21. Benditt EP, Barrett T, McDougall JK. Viruses in the etiology of atherosclerosis. Proc Natl Acad Sci USA 1983; 80: 6386-6389.
22. Murray LM, Bamford KB, O'Reilly DPJ, McCrum EE, Evans AE. Helicobacter pylori infection: relation with cardiovascular risk factors, ischeamic heart disease, and social class. Br Heart J 1995; 74: 497-501.
23. Gurfinkel E. Open and controlled intervention trials for anusual antichlamydia indications: asthma, atherosclerosis, myocardial infarction. En: Allegra L, Blasi F, editores. Chlamydia pneumoniae. Milán, Italia: Springer-Verlag, 1999; 185-187.
24. Anestad G, Scheel O, Hungnes O. Chronic infection and coronary artery disease [carta]. Lancet 1997; 350: 1028.
25. Grayston JT, Kuo C, Wang S, Altman J. A new Chlamydia psittacii strain. TWAR, isolated in acute respiratory tract infections. N Engl J Med 1986; 315: 161-168.
26. Aldous MB, Grayston JT, Wang A, Foy H. Seroepidemiology of Chlamydia pneumoniae TWAR in Seattle Families, 1966-79. J Infect Dis 1992; 166: 646-649.
27. Muhlestein JB, Anderson JL, Hammond EH, Zau L, Trehan S, Schwobe EP et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azythromycin prevents it in a rabbit model. Circulation 1998; 97: 633-636.
28. Epstein SE, Speir E, Zhou YF, Guetta E, Leon M, Finkel T. The role of infection in restenosis and atherosclerosis: focus on cytomegalovirus. Lancet 1996; 348: S13-S16.
29. Speir E, Modali R, Huang ES. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science 1994; 265: 391-394.
30. Sung JJ, Sanderson JE. Hyperhomocysteinaemia, Helicobacter pylori, and coronary heart disease. Heart 1996; 76: 305-307.
31. Metzler B, Schett G, Kleindienst R, Van der Zee R, Ottenhoff T. Hajeer A et al. Epitope specificity of anti-heat shock protein 65/60 serum antibodies in atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17: 536-541.
32. Gurfinkel E. Link between intracellular pathogens and cardiovascular diseases. Clin Microbiol Infect 1998; 4: S33-S36.
33. Jones RB. Chlamydia trachomatis. En: Mandel GL, Bennet JE. Dolin R, editores. The principles and practice of infectious diseases. Nueva York: Churchill Livingstone, 1995; 1679-1693.
34. Gurfinkel E, Bozovich G. Chlamydia pneumoniae, inflammation and the instability of the atherosclerotic plaque. Atherosclerosis 1998; 140 (Supl 1): 31-35.
35. Leinonen M. Pathogenetic mechanisms and epidemiology of Chlamydia pneumoniae. Eur Heart J 1993; 14 (Supl K): 57-61.
36. Buchmaier K, Neu N, De la Mata LM, Pal S, Hessel A, Penninger JM. Chlamydia infections and heart disease linked through antigenic mimicry. Science 1999; 2838: 1335-1339.
37. Ericson K, Saldeen TGP, Lindquist O, Pahlson C, Mehta JL. Relationship of Chlamydia pneumoniae infection to severity of human coronary atherosclerosis. Circulation 2000; 101: 2568-2571.
38. Gurfinkel E, Bozovich G. Emerging role of antibiotics in atherosclerosis. Am Heart J 1999; 138: S537-S538.
39. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm J. Elevated Chlamydia pneumoniae antibodies, cardiovascular events and azithromycin in male survivors of myocardial infarction. Circulation 1997; 96: 404-407.
40. Anderson JL, Muhlestein JB, Carlquist J, Allen A, Trehan S, Nielson C el al. Randomized secondary prevention trial of azythromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection. Circulation 1999; 99: 1540-1547.
41. Gurfinkel E, Bozovich G, Mautner B. Chlamydia pneumoniae in coronary artery disease [carta]. Circulation 2000 14; 101: E95.
42. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B. Randomized trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study. Lancet 1997; 350: 404-407.
43. Raimondi E, Gurfinkel E, Bozovich G, Padrós K, Rodríguez B, Berardi G et al. Coronary artery disease in Argentina. En: Gjertson DW, Terasaki PJ, editores. HLA Nueva York: American Society for Histocompatibility and Immunogenetic, 1998.
44. Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Mautner B. The impact of inflammation and infection on the clinical outcome of patients with symptomatic coronary atherosclerotic disease. The final report of the ROXIS study. Eur Heart J 1999; 20: 121-127.
45. Saikku P, Mattila K, Huttunen MS, Leinonen MS, Nieminen MS, Ekman MR et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; 2: 983-986.
46. Ramírez JA. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. The Chlamydia pneumoniae/Atherosclerosis Study Group. Ann Intern Med 1996; 125: 979-982.
47. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet 1997; 350: 430-436.
48. Kuo CC, Grayston JT, Campbell LA, Goo YA, Wissler RW, Benditt EP. Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15-34 years old). Proc Natl Acad Sci USA 1995; 92: 6911-6914.
49. Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis- An assessment of the evidence and need for future research. Circulation 1997; 96: 4095-4103.